LncRNA LINC01094 contributes to glioma progression by modulating miR-224-5p/CHSY1 axis

被引:0
|
作者
Luotong Liu
Qian Xu
Yu Xiong
Huajiang Deng
Jie Zhou
机构
[1] Affiliated Hospital of Southwest Medical University,Department of Neurosurgery
来源
Human Cell | 2022年 / 35卷
关键词
Glioma; Progression; LncRNA LINC01094; MiR-224-5p; CHSY1;
D O I
暂无
中图分类号
学科分类号
摘要
Glioma serves as the most common malignancy influencing modern people and is associated with severe morbidity and high mortality. Long non-coding RNAs (lncRNAs) as crucial regulators participate in multiple cancer progression. However, the role of lncRNA LINC01094 in the development of glioma remains unclear. Here, we aimed to explore the effect of lncRNA LINC01094 on the glioma progression and the underlying mechanism. Significantly, we revealed that the expression levels of LINC01094 were elevated in the glioma patient tissues compared to adjacent normal tissues. The LINC01094 expression was enhanced in the glioma cell lines. The depletion of LINC01094 inhibited cell viability and colony formation in the glioma cells. Meanwhile, the migration and invasion of glioma cells were impaired by the depletion of LINC01094. Mechanically, we identified that LINC01094 was able to sponge the miR-224-5p in the glioma cells and miR-224-5p inhibitor could reverse the effect of LINC01094 on glioma progression. In addition, miR-224-5p targeted CHSY1 and LINC01094 up-regulated CHSY1 by targeting miR-224-5p in the glioma cells. LINC01094 promoted glioma progression by the positive regulation of CHSY1. Moreover, tumorigenicity analysis showed that LINC01094 enhanced tumor growth of glioma in vivo. Thus, we conclude that lncRNA LINC01094 promotes glioma progression by modulating miR-224-5p/CHSY1 axis. Our finding provides new insights into the mechanism by which lncRNA LINC01094 contributes to the development of glioma, improving the understanding of lncRNA LINC01094 and glioma. LncRNA LINC01094, miR-224-5p, and CHSY1 may serve as potential targets for glioma.
引用
收藏
页码:214 / 225
页数:11
相关论文
共 50 条
  • [21] LncRNA CD27-AS1 promotes acute myeloid leukemia progression through the miR-224-5p/PBX3 signaling circuit
    Tao, Yanling
    Zhang, Jingjing
    Chen, Lulu
    Liu, Xin
    Yao, Mingkang
    Zhang, Hao
    CELL DEATH & DISEASE, 2021, 12 (06)
  • [22] The role of LINC00094/miR-224-5p (miR-497-5p)/Endophilin-1 axis in Memantine mediated protective effects on blood-brain barrier in AD microenvironment
    Zhu, Lu
    Lin, Meiqing
    Ma, Jun
    Liu, Wenjing
    Gao, Lili
    Wei, Shanshan
    Xue, Yixue
    Shang, Xiuli
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2019, 23 (05) : 3280 - 3292
  • [23] LncRNA-ZFAS1 contributes to colon cancer progression through the miR-150-5p/VEGFA axis
    Chen, X.
    Wang, S.
    ANNALS OF ONCOLOGY, 2018, 29
  • [24] LncRNA-NNT-AS1 contributes to the progression of glioma by miR-582-5p/EZH2 axis (vol 73, pg 473, 2021)
    Pan, Tonglin
    Xue, Min
    CYTOTECHNOLOGY, 2024, 76 (05) : 615 - 617
  • [25] LncRNA NFIA-AS2 promotes glioma progression through modulating the miR-655-3p/ZFX axis
    Jun Xin
    Yu-Hong Zhao
    Xi-Yun Zhang
    Li-Qiang Tian
    Human Cell, 2020, 33 : 1273 - 1280
  • [26] LncRNA NFIA-AS2 promotes glioma progression through modulating the miR-655-3p/ZFX axis
    Xin, Jun
    Zhao, Yu-Hong
    Zhang, Xi-Yun
    Tian, Li-Qiang
    HUMAN CELL, 2020, 33 (04) : 1273 - 1280
  • [27] LncRNA MEG8 promotes NSCLC progression by modulating the miR-15a-5p-miR-15b-5p/PSAT1 axis
    Guo, Kai
    Qi, Di
    Huang, Bo
    CANCER CELL INTERNATIONAL, 2021, 21 (01)
  • [28] LncRNA MEG8 promotes NSCLC progression by modulating the miR-15a-5p-miR-15b-5p/PSAT1 axis
    Kai Guo
    Di Qi
    Bo Huang
    Cancer Cell International, 21
  • [29] Hsa_circ_0134111 promotes osteoarthritis progression by regulating miR-224-5p/CCL1 interaction
    Liu, Yongbao
    Zhang, Yanxiu
    AGING-US, 2021, 13 (16): : 20383 - 20394
  • [30] HCC control by lycorine-based restraining of the MiR-224-5p/COLEC10 axis
    Chen, Cai
    Zhao, Junjie
    Qiu, Bo
    PAKISTAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2024, 37 (05) : 1093 - 1105